Search
Nerofe
go.drugbank.com/drugs/DB14786InvestigationalNerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).
Synonyms: WWTFFLPSTLWERK, (ALL D)-, TRP-TRP-THR-PHE-PHE-LEU-PRO-SER-THR-LEU-TRP-GLU-ARG-LYS, (ALL D)-Dapansutrile
go.drugbank.com/drugs/DB16130InvestigationalDapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
Abt-925 anhydrous free base
go.drugbank.com/drugs/DB33803InvestigationalCategories: Receptors, Dopamine D3, antagonists & inhibitorsSabirnetug
go.drugbank.com/drugs/DB19438InvestigationalSabirnetug is under investigation in clinical trial NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)).
Psilocybin
go.drugbank.com/drugs/DB11664InvestigationalIn November, 2019, it was granted Breakthrough Therapy status by the FDA.
INVAC-1
go.drugbank.com/drugs/DB16196InvestigationalINVAC-1 is under investigation in clinical trial NCT03265717 (DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (Htert), Invac-1 in Chronic Lymphocytic Leukemia).
Synonyms: Human telomerase reverse transcriptase (htert) dna vaccine invac-1, Invac-1, a double stranded dna plasmid vaccine construct encoding ubiquitin-human telomerase reverse transcriptase (htert) fusion proteinZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalThe vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest[L16503]. … The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758].
αAβ–Gas6
go.drugbank.com/drugs/DB17069Experimentalof AD. … It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand
Blonanserin
go.drugbank.com/drugs/DB09223InvestigationalAs a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.
Categories: Dopamine D2 Receptor AntagonistsTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalagent, via a protease-cleavable valine-citrulline linker. … On April 29, 2024, tisotumab vedotin was granted full FDA approval.